Post-marketing surveillance and safety updates It is essential to monitor the drugs when they are ready to be picked up for any additional safety issues
At least three other states California, New Hampshire and North Carolina have recently limited or plan to throttle access to GLP-1s for weight-loss, according to health policy think tank KFF
Cognitive rehabilitation in bipolar spectrum disorder: a systematic review
Still, challenges remain, which include relatively high discontinuation rates that appear to be the result of adverse side effects, as well as questions pertaining to pricing and insurance coverage once the product is approved by the Food and Drug Administration
Florida Blue, UnitedHealthcare, Aetna, Cigna, and Humana may offer coverage depending on your plan
Monney, M., et al